Literature DB >> 6445228

Isolation of a cellular subpopulation from a human colonic carcinoma cell line.

P M Kimball, M G Brattain.   

Abstract

A population of cells with increased resistance to 5-fluorouracil was isolated from cultures of the human colonic carcinoma cell line HT29. The resistant cells (HTFU) showed an altered morphology by light and electron microscopy and demonstrated contact inhibition in vitro. DNA assays and chromosome counts showed that HT29 cultures exhibit both hyper- and hypoaneuploidy, while HTFU cultures appear exclusively hypoaneuploid. One year after the isolation of HTFU, both cell lines showed equal sensitivity to 5-fluorodeoxyuridine while HTFU cells retained comparative insensitivity to 5-fluorouracil. Carcinoembryonic antigen production was not demonstrated in pre- or postconfluent cultures of HTFU, although carcinoembryonic antigen was present in both cells and media of HT29 cultures. Growth in semisolid medium was demonstrated for both cultures; however, HTFU showed a lower plating efficiency than did HT29. Tumors were observed in all of the nude mice given injections of HT29 or HTFU cells. Tumors formed from HTFU cells were smaller, and frequently the primary site receded after 6 to 8 weeks; Although in vitro tests suggested a reduced tumorigenic potential for HTFU cells, metastasis was observed only in mice given injections of cells from the HTFU line.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6445228

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97.

Authors:  Y Li; Z Y Tang; S L Ye; Y K Liu; J Chen; Q Xue; J Chen; D M Gao; W H Bao
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

2.  Tumor heterogeneity: biological implications and therapeutic consequences.

Authors:  G H Heppner; B E Miller
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

3.  Characterization of an unusual isoenzyme of N-acetyl-beta-D-hexosaminidase from a human colonic carcinoma cell line.

Authors:  P M Kimball; M G Brattain; W E White
Journal:  Biochem J       Date:  1981-01-01       Impact factor: 3.857

Review 4.  Immunology of metastasis. Can the immune response cope with disseminated tumor?

Authors:  P Frost; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

5.  Expression of proliferating cell nuclear antigen and CD44 variant exon 6 in primary tumors and corresponding lymph node metastases of colorectal carcinoma with Dukes' stage C or D.

Authors:  Ji-Cheng Zhang; Zuo-Ren Wang; Yan-Juan Cheng; Ding-Zhong Yang; Jing-Sen Shi; Ai-Lin Liang; Ning-Na Liu; Xiao-Min Wang
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

6.  The clinical significance of regional variations in histologic differentiation within carcinomas of the colorectum.

Authors:  H Kotanagi; T Fukuoka; Y Shibata; T Yoshioka; O Aizawa; K Koyama
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

7.  Development of highly immunogenic variants of a rat fibrosarcoma line during in vitro cultivation.

Authors:  K Yamashina; T Oikawa; M Kasai; M Naiki; I Chiba; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 8.  In vitro growth characteristics associated with benign and metastatic variants of tumor cells.

Authors:  M A Cifone
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264

9.  Establishment and characterization of a new human colon adenocarcinoma cell line: BCS-TC2.

Authors:  J Turnay; N Olmo; J G Gavilanes; J Benitez; M A Lizarbe
Journal:  Cytotechnology       Date:  1990-01       Impact factor: 2.058

10.  Intra-tumoral heterogeneity of tumour potential doubling times (Tpot) in colorectal cancer.

Authors:  M S Wilson; C M West; G D Wilson; S A Roberts; R D James; P F Schofield
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.